LinkedUp, TianTi end le­gal dis­pute with Adimab over yeast-based an­ti­body plat­form

LinkedUp Bio­science and TianTi Bio­ther­a­peu­tics have re­solved their le­gal bat­tle with Adimab dat­ing back to 2020 con­cern­ing al­leged mis­use of trade se­crets.

The de­fen­dants, both …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER